# EDGAR Filing Document

**Accession Number:** 0000724445
**File Stem:** 0001410578-25-002050
**Filing Date:** 2025-9
**Character Count:** 7570
**Document Hash:** 65a310b71acb3a43b630418b7454758c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001410578-25-002050.hdr.sgml**: 20250911

**ACCESSION NUMBER**: 0001410578-25-002050

**CONFORMED SUBMISSION TYPE**: 8-K/A

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250721

**ITEM INFORMATION**: Changes in Registrant's Certifying Accountant

**FILED AS OF DATE**: 20250911

**DATE AS OF CHANGE**: 20250911

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BURZYNSKI RESEARCH INSTITUTE INC
- **CENTRAL INDEX KEY:** 0000724445
- **STANDARD INDUSTRIAL CLASSIFICATION:** IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 760136810
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0228

**FILING VALUES:**
- **FORM TYPE:** 8-K/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-23425
- **FILM NUMBER:** 251308711

**BUSINESS ADDRESS:**
- **STREET 1:** 12000 RICHMOND AVE
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77082
- **BUSINESS PHONE:** (713) 335-5697

**MAIL ADDRESS:**
- **STREET 1:** 9432 KATY FREEWAY
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77055

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K/A**

**(Amendment No. 1)**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**July 21, 2025**

**Date of Report (Date of earliest event reported)**

**Burzynski Research Institute, Inc.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **000-23425** | **76-0136810** |
| **(State or other jurisdiction<br> of incorporation)** | **(Commission**<br> **File Number)** | **(I.R.S. Employer**<br> **Identification Number)** |

---

**9432 Katy Freeway, Suite 200, Houston, TX 77055**

**(Address of principal executive offices)**

**(713) 335-5697**

**(Registrant's telephone number, including area code)**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

---

| |
|:---|
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

---

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which<br> registered |
| None | BZYR | None |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§240.12b–2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

**EXPLANATORY NOTE**

On July 24, 2025, Burzynski Research Institute, Inc. (the "Company") filed a Current Report on Form 8-K (the "Original Report") to report the resignation of Pannell Kerr Forster of Texas, P.C. ("PKF") as the Company's independent registered public accounting firm on July 21, 2025, and related matters under Item 4.01 of Form 8-K.

The Company hereby amends the Original Report by filing this Amendment No. 1 on Form 8-K/A to include disclosures regarding the appointment of new independent registered auditors of the Company, as required under Item 4.01(b).

Item 4.01 of the Original Report is amended and restated in its entirety as set forth below.

Except as set forth herein, no other modifications have been made to the Original Report.

---

| | |
|:---|:---|
| **Item 4.01** | **Changes in Registrant's Certifying Accountant.** |

---

(a) <u>Resignation of Previous Independent Registered Public Accounting Firm</u>

On July 21, 2025, the Company received notice from PKF, the Company's independent registered public accounting firm, notifying the Company that PKF had been recently acquired by another accounting firm and would not be able to act as the Company's registered public accounting firm in the future. As such, the effective date of such resignation was July 21, 2025.

During the Company's two most recent fiscal years (ended February 28, 2025 and February 29, 2024) and the subsequent interim period through May 31, 2025, there were no "disagreements" (within the meaning of Item 304(a)(1)(iv) of Regulation S-K and the related instructions under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) between the Company and PKF on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of PKF, would have caused PKF to make reference to the subject matter of the disagreements in its reports on the financial statements of the Company for such years. Also during this same period, there were no "reportable events" (within the meaning of Item 304(a)(1)(v) of Regulation S-K and the related instructions under the Exchange Act).

The Company has provided PKF with a copy of the foregoing disclosures under Item 4.01 on Form 8-K prior to filing it with the U.S. Securities and Exchange Commission ("SEC") and has requested that PKF furnish the Company with a letter addressed to the SEC stating whether it agrees with the statements made by the Company under Item 4.01 of this Form 8-K. A copy of PKF's letter, dated July 24, 2025, was filed as Exhibit 16.1 in the Original Report and incorporated herein by reference.

(b) <u>Engagement of New Independent Registered Public Accounting Firm</u>

On September 9, 2025, the Board of Directors of the Company approved the engagement of M&K CPA's PLLC ("M&K") as the independent registered public accounting firm for the Company for the fiscal year ending February 28, 2026. During the Company's two most recent fiscal years (ended February 28, 2025 and February 29, 2024) and the subsequent interim period prior to the engagement of M&K, neither the Company, nor anyone on the Company's behalf consulted with M&K regarding (1) the application of accounting principles to a specified transaction, either completed or proposed; (2) the type of audit opinion that might be rendered on the Company's financial statements; or (3) the subject of any "disagreement," as defined in Item 304(a)(1)(iv) of Regulation S-K under the Exchange Act and the instructions thereto, or a "reportable event," as defined in Item 304(a)(1)(v) of Regulation S-K under the Exchange Act.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: September 11, 2025 | **BURZYNSKI RESEARCH INSTITUTE, INC.** | **BURZYNSKI RESEARCH INSTITUTE, INC.** |
|  | By: | /s/ Stanislaw R. Burzynski |
|  |  | Stanislaw R. Burzynski |
|  |  | President and Chairman of the Board of Director |

---